Daniel Chen, Synthetic Design Lab CEO
April 23, 2025 07:30 AM EDTUpdated 08:10 AM
Financing
Startups

Genen­tech vet launch­es ADC start­up with $20M

Lei Lei Wu

News Reporter

A Bay Area pro­tein de­sign start­up wants to build more po­tent an­ti­body-drug con­ju­gates, and is start­ing with $20 mil­lion in seed fund­ing.

The com­pa­ny, Syn­thet­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

Reper­toire inks au­toim­mune deal with Genen­tech as it eyes a re­turn to the clin­ic

Ex­clu­sive: Chica­go start­up Grove Bio­phar­ma nabs $30M Se­ries A

Eli Lil­ly sues four tele­health com­pa­nies sell­ing com­pound­ed tirzepatide

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times